Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Overview Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Companies Involved in Therapeutics Development Aurigene Discovery Technologies Ltd Beta Pharma Inc Cyclacel Pharmaceuticals Inc Qurient Co Ltd Syros Pharmaceuticals Inc Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Drug Profiles BS-181L - Drug Profile Product Description Mechanism Of Action R&D Progress CT-7001 - Drug Profile Product Description Mechanism Of Action R&D Progress sapacitabine + seliciclib - Drug Profile Product Description Mechanism Of Action R&D Progress seliciclib - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CDK7 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CDK7 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CDK7 for Small Cell Lung Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress SY-1365 - Drug Profile Product Description Mechanism Of Action R&D Progress TG-02 - Drug Profile Product Description Mechanism Of Action R&D Progress Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Divi

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Aurigene Discovery Technologies Ltd, H1 2018 Pipeline by Beta Pharma Inc, H1 2018 Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018 Pipeline by Qurient Co Ltd, H1 2018 Pipeline by Syros Pharmaceuticals Inc, H1 2018 Dormant Projects, H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018

Aurigene Discovery Technologies Ltd Beta Pharma Inc Cyclacel Pharmaceuticals Inc Qurient Co Ltd Syros Pharmaceuticals Inc